What is the evidence for the efficacy and safety of oral pregnenolone?

Evidence for Oral Pregnenolone

Based on emerging research evidence, oral pregnenolone shows promise for specific psychiatric and substance use conditions, particularly in reducing craving and negative symptoms, though it lacks FDA approval for these indications and should be considered investigational.

Key Clinical Applications with Evidence

Substance Use Disorders

Cocaine Use Disorder (CUD)

• Pregnenolone at 300-500 mg/day significantly reduces stress- and cue-induced cocaine craving in treatment-seeking individuals 1, 2
• The 300 mg/day dose demonstrated superior outcomes, with significantly lower amounts of cocaine used compared to both 500 mg/day and placebo over 8 weeks 2
• Both doses normalize stress-induced HPA axis dysfunction and reduce autonomic arousal (heart rate, blood pressure) that typically accompanies craving 1
• Bioavailability concerns are addressed: twice-daily dosing achieves stable, sustained plasma levels over 32.5 hours with strong correlations between dosing and levels at 2,4,6, and 8 hours post-administration 3

Alcohol Use Disorder (AUD)

• Pregnenolone 300-500 mg/day reduces both stress- and alcohol cue-provoked craving 4
• The 300 mg/day dose specifically reduced stress-induced anxiety 4
• Both doses normalized cortisol/ACTH ratios and increased stress-induced cardiovascular responses relative to neutral conditions, suggesting restoration of adaptive stress biology 4

Psychiatric Disorders

Bipolar Depression

• In a 12-week RCT (n=80), pregnenolone titrated to 500 mg/day showed significant treatment-by-week interaction on Hamilton Depression Rating Scale (p=0.025) 5
• Remission rates were significantly higher with pregnenolone (61%) versus placebo (37%) as measured by IDS-SR (p=0.046) 5
• Changes in allopregnanolone and pregnanolone levels correlated negatively with anxiety reduction (r=-0.43 to -0.48, p<0.036) 5

Recent-Onset Schizophrenia/Schizoaffective Disorder

• Pregnenolone 50 mg/day (notably lower dose than substance use studies) significantly reduced negative symptoms with moderate effect size (d=0.79) 6
• Effects were most pronounced at weeks 6-8, particularly in patients NOT on concomitant mood stabilizers (p=0.010) 6
• Specific improvements in blunted affect, avolition, and anhedonia domains (d=0.57) 6
• Trial completion rate was 86.7%, indicating good tolerability 6

Dosing Considerations

Effective dose ranges vary by indication:

• Substance use disorders: 300-500 mg/day divided twice daily, with 300 mg/day showing optimal risk-benefit profile 1, 2
• Bipolar depression: 500 mg/day 5
• Schizophrenia: 50 mg/day 6

The substantial dose differences suggest condition-specific mechanisms and the need for tailored dosing strategies.

Safety Profile

Pregnenolone demonstrates excellent tolerability across studies:

• No serious adverse events reported in any trials
• Trial completion rates: 90-100% across studies 5, 6, 2
• Well-tolerated as add-on therapy to existing psychiatric medications 5, 6
• No significant drug interactions noted with antipsychotics, benzodiazepines, or mood stabilizers 6

Mechanism of Action

Pregnenolone functions as a neurosteroid precursor that:

• Converts to allopregnanolone and pregnanolone, which potentiate GABAergic transmission
• Normalizes HPA axis dysfunction associated with chronic substance use 4, 1
• Reduces stress-induced autonomic arousal 1
• May restore neuroactive steroid levels depleted by chronic alcohol or cocaine use

Critical Limitations

Important caveats for clinical application:

• All evidence comes from small pilot studies (n=30-80); larger confirmatory trials needed
• No FDA-approved indications for psychiatric or substance use conditions
• Optimal dosing, treatment duration, and long-term safety remain undefined
• The drug labels provided 7 refer to prednisolone (a corticosteroid), NOT pregnenolone, indicating no FDA-approved oral pregnenolone formulation currently exists for these indications
• Recent preclinical data suggests pregnenolone may promote tumor immune evasion 8, though clinical relevance is unknown

Clinical Bottom Line

For treatment-resistant cases of cocaine use disorder, alcohol use disorder, or bipolar depression where standard therapies have failed, pregnenolone 300-500 mg/day represents a reasonable off-label option with preliminary efficacy data and favorable safety profile. The 300 mg/day dose appears optimal for substance use disorders. For negative symptoms in recent-onset schizophrenia, 50 mg/day shows benefit, particularly in patients not on mood stabilizers. However, patients must understand this represents investigational use of a non-FDA-approved treatment, and close monitoring is essential.